---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-041082"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:55:13.034161+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Q1 net loss narrows to $9.7M; Alzheimer's Phase 2 data expected late June

## Summary
- Net loss $9.7M ($0.42 per share) vs $11.0M YoY; R&D expenses down to $7.6M from $8.7M.
- Cash $19.3M at March 31; raised $2.1M post-quarter via stock sale; 23.2M shares outstanding.
- Top-line results from Phase 2 Alzheimer's trial (MINDFuL) expected in second half of June.
- Plans to file BLA for CORDStrom in RDEB in early 2026; partnered with Catapult for manufacturing scale-up.
- INKmune Phase I completed, Phase II opened; safety endpoint met; trial expanded to VA Health System.

## SEC filing metadata
- accession: 0001213900-25-041082
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025041082/0001213900-25-041082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025041082/ea0241453-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-041082
- JSON: https://secwatch.observer/filing/0001213900-25-041082.json
- Plain text: https://secwatch.observer/filing/0001213900-25-041082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.